23
A C T I N G | T O G E T H E R |
BioNTech | Annual Report 2023 | 2 |
1MAGAZINE | 05 | 41 | 48 |
05 | 11 | 14 | 18 | 25 | 30 | 41 | 48 | 60 |
EXPLORING | OUR PIPELINE | FACTS AND | LETTER | INTERVIEW WITH | REPORT OF THE | FROM FOUNDING | 2023 HIGHLIGHTS FINANCIAL | |
THE POWER OF | FIGURES | FROM THE | HELMUT JEGGLE | SUPERVISORY | VISION TO | CALENDAR, | ||
COMBINATION | MANAGEMENT | AND UGUR SAHIN | BOARD | GLOBAL IMPACT | IMPRINT | |||
BOARD |
BioNTech | Annual Report 2023 | 3 |
2 | 3 | 4 | INDEPENDENT |
AUDITOR'S REPORT | |||
CONSOLIDATED | |||
FINANCIAL | |||
STATEMENTS | |||
INDEPENDENT | |||
AUDITOR'S REPORT | |||
5REMUNERATION | |||
REPORT |
62 | 115 | 217 | 249 |
COMBINED MANAGEMENT | GROUP REPORT 2023 | COMPENSATION REPORT | FURTHER INFORMATION |
REPORT 2023 | 2023 |
FINANCIAL REPORT
BioNTech | Annual Report 2023
Bispecific antibodies are protein molecules that can bind two different targets, bringing closer for example the cancer cell to the immune cell. When in close proximity of the cancer cell, the immune cell could recognize and orchestrate its elimination.
4
MAGAZINE1
BioNTech | Annual Report 2023 | 5 |
EXPLORING THE POWER OF COMBINATION
Our vision for future precision cancer treatments: We are developing a unique therapy toolbox designed to act together and with the aim to improve outcomes for patients.
BioNTech | Annual Report 2023 | 6 |
1 THE CHALLENGE //
When a physician discusses a potential treatment plan with a patient who has just been diagnosed with cancer, they know that they will have to treat a disease with many different facets. Cancer cells are physically different from healthy cells in the body. Their shapes and properties are mutated and changed. They interact differently with their environment to grow abnormally and survive. And in each growing cycle, they have the potential to change further. The cells in the same tumor within the same patient can also be different. Medicine faces the challenge that every tumor is unique.
DNA MUTATION | DNA MUTATION |
2 THE CONSEQUENCE //
As a consequence, a standard of care might work for one, but not another patient. In other cases, the constant changes of the tumor cells lead to a resistance to available treatments. What may have originally given good results and helped the patient might not work over time. For example, it is estimated that more than 90% ofmortalitiesin cancer patients can be attributed to chemotherapy resistance.
Helping patients and addressing unmet medical needs is what drives us at BioNTech every day. We have been spending years on better understanding tumors' differences as well as the immune system's mechanisms to develop potential cancer treatments. We believe that the limitations cannot be overcome by a single technology, but rather a therapy toolbox.
SHARED | CLDN6 | PD-L1 | HER-2 | EPCAM | PATIENT- |
TUMOR | INDIVIDUAL | ||||
TARGET | TUMOR | ||||
TPTE | TARGET |
BioNTech | Annual Report 2023
3 OUR APPROACH //
Targeted therapies //
Cell therapies are designed to equip certain immune cells of the patients physically with structures (recep- tors), enabling them to recognize cancer cells and orchestrate their elimination.
Antibody-drug conjugates (ADCs) are designed to targetedly deliver a chemotherapy to tumor cells. Unlike traditional chemotherapy, cancer treatments with ADCs are designed to minimize the impact on healthy cells.
7
SELECTED TARGETS
HER-2CLDN6
We work on potential treatment approaches that aim to precisely target the specific tumor features by employing a different mechanism to tackle each feature. Our approach is to combine therapies - some investigational and some approved - with the aim of achieving better results compared to the current standard of care. This is why we are developing a suite of technologies which we call our oncology toolbox.
SELECTED TARGETS
SYNER
GY
SYNERGETIC
SPACE FOR
CURATIVE
APPROACHES
SYNERGY
GY | |
R | |
E | |
N | |
SY |
SHARED | PATIENT- INDIVIDUAL | |
TUMOR | TUMOR | |
TARGET TPTE | TARGET | mRNA vaccines// |
Immuno-modulators //
SELECTED TARGETS
PD-L1EpCAM
mRNA vaccines are designed to teach the immune | Mono- and bispecific antibodies are designed to |
system about features on the surface of cancer cells | modulate the activity of immune cells and in some |
(targets), supporting immune cells to recognize and | cases cancer cells, enhancing the immune response |
destroy them. | against cancer cells. |
Simplified illustration
BioNTech | Annual Report 2023
investigational cell therapy
B NT211
8
We have been evaluating combinational therapies since 2014. Here is a selection of a few currently running clinical trials:
BNT211 //
The product candidate BNT211 combines a CAR-T cell therapy candidate with an mRNA vaccine candidate. For the CAR-T cell therapy candidate, patients' certain immune cells are equipped with a receptor to recognize the target protein CLDN6 and precisely attack cancer cells. The mRNA vaccine candidate encodes for CLDN6 and is designed to stimulate these CAR-T cells' persistence and functionality in the body, complementing the CAR-T cells in a synergistic manner. This approach is aimed at more efficient recognition and elimination of cancer cells. BNT211 is currently being evaluated in Phase 1/2 clinical trials in patients with germ cell tumors.
Claudin-6 (CLDN6) is a surface protein expressed | |
on multiple solid tumors such as ovarian cancer, | |
sarcoma, testicular cancer, endometrial cancer | |
mRNA vaccine candidate | and gastric cancer. |
BioNTech | Annual Report 2023
individualized mRNA vaccine candidate
BNT122 + CHECKPOINT INHIBITOR
checkpoint inhibitor
9
AUTOGENE CEVUMERAN/BNT1221
+ CHECKPOINT INHIBITOR //
This potential treatment approach combines two different molecules to fight cancer. The individualized mRNA vaccine candidate BNT122 is designed to provide immune cells with information about the patient's unique cancer cells and induce an immune response against the tumor. The checkpoint inhibitor is an antibody that keeps cancer cells from suppressing immune cells. This combinatory approach is intended to lead to a stronger and more specific immune response and elimination of cancer cells. BNT122 is currently being evaluated in Phase 2 clinical trials in patients with melanoma.
- In collaboration with Genentech, a member of the Roche Group.
Attachments
- Original Link
- Original Document
- Permalink
Disclaimer
BioNTech SE published this content on 03 May 2024 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 03 May 2024 00:20:07 UTC.